Watch for Phase 1 healthy volunteer data from EVO570 expected mid-2027 and the start of the Phase 2 RA trial. Novartis' VAV1 program (MRT-6160) may provide class validation as early as Q4 2027-Q1 2028. The PIPE at $6.04/share sets a near-term reference price.
Drug in focus
EVMN drug pipeline →EVO570
● neutral Named in this 8-K- Impact
- Phase
- Preclinical (Phase 1 imminent)
- Time to market
- Multiple years if successful. The drug has not yet entered Phase 1. Assuming positive Phase 1 results and a Phase 2 start in 2H 2027, Phase 3 trials would follow, putting a potential approval at earliest several years out (likely 2030+).
- Next catalyst
- None dated
What to watchThe key near-term event to watch is the formal announcement of Phase 1 first-patient-dosed (expected January 2027). A successful start would signal the molecule is safe enough for human testing. The more consequential catalyst will be Phase 1 safety and PK/PD data around mid-2027, which will provide the first human proof-of-mechanism for VAV1 degradation. Investors should also monitor how the Phase 2 Sjogren's data for Novartis' competing VAV1 degrader MRT-6160 reads out, as positive results would validate the target but also increase competitive pressure.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 5 $6.37entry
- T+1 · 4d ago +4.40%α +4.08% · $6.65
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evommune in-licensed EVO570, an oral VAV1 molecular glue degrader, from Hinova Pharmaceuticals for $30M upfront ($20M cash + $10M in pre-funded warrants) plus up to ~$1.1B in milestones and tiered royalties. Concurrently, it raised ~$30M in a private placement of 4,966,889 shares at $6.04 per share. The combined transactions add a Phase 1-ready asset and extend cash runway into 2H 2029.
Key Financial Metrics
Key Facts
- Evommune in-licensed EVO570 (VAV1 MGD) from Hinova for $20M cash + $10M in pre-funded warrants upfront
- Up to $150M in development/regulatory milestones and up to $920M in commercial milestones plus tiered mid-single to low-double digit royalties
- Concurrent $30M private placement of 4,966,889 shares at $6.04 per share to institutional investors
- Pro forma cash, cash equivalents and investments estimated at ~$292.3M post-closing, funding operations into 2H 2029
- Phase 1 trial of EVO570 expected to begin imminently; Phase 2 in RA planned for 2027
- Warrants to Hinova for up to 1,262,413 shares at $0.001 per share, exercisable until November 4, 2036, with a 4.99% beneficial ownership limitation
Financial Impact
$30M upfront ($20M cash + $10M warrants) plus up to ~$1.07B in milestones; $30M gross PIPE proceeds; pro forma cash ~$292.3M
Risk Factors
- EVO570 is preclinical/Phase 1-stage with no clinical efficacy data yet; Phase 1 safety/PK data due mid-2027
- Upfront and milestone payments will increase operating burn; total milestone obligations are large relative to current market cap
- Warrant exercise could add up to 1.26M shares (dilution ~2.5% based on current shares outstanding implied by market cap and price)
- Novartis' MRT-6160 is ahead in development; competitive landscape includes InnoCare and Haisco in China
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447608 |
| Document: evmn-ex4_1.htm | 0001193125-26-447608 |
| Document: evmn-ex10_2.htm | 0001193125-26-447608 |
| Document: evmn-20261104.htm | 0001193125-26-447608 |
| Document: evmn-ex99_1.htm | 0001193125-26-447608 |
| Document: evmn-ex99_3.htm | 0001193125-26-447608 |
| Document: evmn-ex99_2.htm | 0001193125-26-447608 |
| Document: 0001193125-26-447608-index-headers.html | 0001193125-26-447608 |
Track record
18 reports on EVMN
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +41.15% at T+60 after the May 28, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 2026today SC 13D/A Neutral 4/10 Entry $7.48 Now $7.84 +4.81% settles Feb 9
- Nov 5, 20265d ago 8-K Neutral 3/10 Entry $6.37 Now $7.84 +23.08% settles Feb 3
- Nov 4, 20266d ago 8-K Neutral 5/10 Viewing Entry $6.37 Now $7.84 +23.08% settles Feb 3
- Oct 1, 20265w ago 8-K Bullish 7/10 Entry $7.21 Now $7.84 +8.74% settles Dec 28
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $9.99 Now $7.84 −21.52% settles Dec 9
- Jul 30, 202614w ago 8-K Neutral 5/10 Entry $11.35 to $5.10 Now $7.84 −30.93% ▼ −55.07% −57.53% vs SPY
- Jul 10, 202617w ago Insider Cluster Neutral 3/10 Entry $12.10 to $6.61 Now $7.84 −35.21% ▼ −45.37% −49.37% vs SPY
- Jun 29, 202619w ago 8-K Bearish 7/10 Entry $15.05 to $9.60 Now $7.84 +47.91% ▲ +36.21% +40.60% vs SPY
- Jun 24, 202619w ago Insider Cluster Neutral 3/10 Entry $24.13 to $9.65 Now $7.84 −67.51% ▼ −60.01% −63.74% vs SPY
- Jun 3, 202622w ago Insider Cluster Bearish 5/10 Entry $20.69 to $13.23 Now $7.84 +62.11% ▲ +36.06% +37.94% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers